Praveer Vyas

Mr. Praveer Vyas


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Bioengineering
Verified
Journal Article
Open access
PDF file
CCCooper Thomas Cheng
Cooper Thomas Cheng
PVPraveer Vyas
Praveer Vyas
E[Edward McClain IV [suffix]
Edward McClain IV [suffix]
THThomay Hoelen
Thomay Hoelen
CAChris Arts
Chris Arts
BCBoyle C. Cheng
Boyle C. Cheng
Bone regeneration is a complex multicellular process involving the recruitment and attachment of osteoprogenitors and their subsequent differentiation into osteoblasts that deposit extracellular matrixes. There is a growing demand for synthetic bone graft materials that can be used to augment these processes to enhance the healing of bone defects resulting from trauma, disease or surgery. P-15 is a small synthetic peptide that is identical in sequence to the cell-binding domain of type I collagen and has been extensively demonstrated in vitro and in vivo to enhance the adhesion, differentiation and proliferation of stem cells involved in bone formation. These events can be categorized into three phases: attachment, activation and amplification. This narrative review summarizes the large body of preclinical research on P-15 in terms of these phases to describe the mechanism of action by which P-15 improves bone formation. Knowledge of this mechanism of action will help to inform the use of P-15 in clinical practice as well as the development of methods of delivering P-15 that optimize clinical outcomes.

11 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ATAmol H Trivedi
Amol H Trivedi
VWVicki Z. Wang
Vicki Z. Wang
E[Edward McClain IV [suffix]
Edward McClain IV [suffix]
PVPraveer Vyas
Praveer Vyas
ISIsaac Swink
Isaac Swink
PDPatrick J. DeMeo
Patrick J. DeMeo
Musculoskeletal (MSK) pathology encompasses an array of conditions that can cause anything from mild discomfort to permanent injury. Their prevalence and impact on disability have sparked interest in more effective treatments, particularly within orthopedics. As a result, the human placenta has come into focus within regenerative medicine as a perinatal derivative (PnD). These biologics are sourced from components of the placenta, each possessing a unique composition of collagens, proteins, and factors believed to aid in healing and regeneration. This review aims to explore the current literature on PnD biologics and their potential benefits for treating various MSK pathologies. We delve into different types of PnDs and their healing effects on muscles, tendons, bones, cartilage, ligaments, and nerves. Our discussions highlight the crucial role of immune modulation in the healing process for each condition. PnDs have been observed to influence the balance between anti- and pro-inflammatory factors and, in some cases, act as biologic scaffolds for tissue growth. Additionally, we assess the range of PnDs available, while also addressing gaps in our understanding, particularly regarding biologic processing methods. Although certain PnD biologics have varying levels of support in orthopedic literature, further clinical investigations are necessary to fully evaluate their impact on human patients.

6 September 2024 in Bioengineering
Verified
Journal Article
Open access
PDF file
BCBoyle C. Cheng
Boyle C. Cheng
ISIsaac Swink
Isaac Swink
CCCooper Thomas Cheng
Cooper Thomas Cheng
OCOwen G. Corcoran
Owen G. Corcoran
VWVicki Z. Wang
Vicki Z. Wang
AYAlexander Yu
Alexander Yu
P-15 is a 15-amino-acid-long biomimetic peptide widely demonstrated to enhance osteogenesis in vivo. Despite the prevalence of polyether-ether-ketone (PEEK) in interbody device manufacturing, a growing body of evidence suggests it may produce an unfavorable immune response. The purpose of this preliminary study was to characterize the immune response and new bone growth surrounding PEEK implants with and without a P-15 peptide-based osteobiologic. A bilateral femoral defect model was conducted using New Zealand white rabbits. A total of 17 test subjects received one implant in each distal femur, either with or without bone graft material. Animals were allowed to survive to 4 or 8 weeks, at which time the femurs were collected and subjected to micro-computer tomography (microCT) or cytokine analysis. MicroCT analysis included the quantification of bone growth and density surrounding each implant. The cytokine analysis of periprosthetic tissue homogenates included the quantification of interleukins (ILs) and TNF-α expression via ELISA kits. Improvements in bone volume were observed in the P-15 cohort for the regions of interest, 500–136 and 136–0 µm from the implant surface, at 8 weeks post-op. Concentrations of IL-1β, IL-4, and IL-6 cytokines were significantly higher in the P-15 cohort compared to the PEEK cohort at the 4-week timepoint. Significant reductions in the concentrations of IL-4 and IL-6 cytokines from the 4- to 8-week cohort were observed in the P-15 cohort only. The P-15 peptide has the potential to modulate the immune response to implanted materials. We observed improvements in bone growth and a more active micro-environment in the P-15 cohort relative to the PEEK control. This may indicate an earlier transition from the inflammatory to remodeling phase of healing.

15 August 2025 in Surgical Neurology International
Verified
Journal Article
Open access
EREthan James Richman
Ethan James Richman
SHSanjiv Harikumar
Sanjiv Harikumar
ILIan Lonich
Ian Lonich
TLTimothy Leichliter
Timothy Leichliter
PVPraveer Vyas
Praveer Vyas
JLJody Leonardo
Jody Leonardo
Background: Management of normal pressure hydrocephalus (NPH) can be complicated by the progression of underlying neurological conditions such as Alzheimer’s disease or Parkinson’s disease. The purpose of this study is to explore the long-term shunting response on gait dysfunction in patients with neurodegenerative NPH, a subtype of NPH occurring in patients with another neurodegenerative condition, as the duration of symptomatic improvement with shunting is unclear in this population. Methods: A retrospective chart review of patients undergoing evaluation for NPH at the Adult Hydrocephalus Center at Allegheny General Hospital was performed. Timed performances on two gait measures, the timed walk and timed up and go, were collected during a 2-day outpatient lumbar tap trial and on follow-up evaluation after shunt placement. Improvements over baseline were calculated at each follow-up and analyzed by years after shunt surgery. Potential sequelae of VPS such as subdural hematomas and infection during the study period were tallied. Results: Patients experienced statistically and clinically significant gait improvements within the first 6 months after surgery. Significant reductions in gait times were not found by the end of the 1st year after surgery through the remainder of the study period. Conclusion: While VPS can provide a limited period of improved gait, it was not shown that shunting can provide persisting benefit in patients with underlying progressive neurodegenerative disease. Shunting to alleviate gait symptoms should be considered on a case-by-case basis with patients and their families in alignment with care goals.

10 October 2025 in Surgical Neurology International
Verified
Journal Article
Open access
SJStephen Jaffeee
Stephen Jaffeee
TKTrent Shane Kite
Trent Shane Kite
SAShaifali Arora
Shaifali Arora
CSChris Sanfillipo
Chris Sanfillipo
PVPraveer Vyas
Praveer Vyas
AWAlexander Whiting
Alexander Whiting
Background: Responsive neurostimulation (RNS) is a promising treatment for drug-resistant epilepsy (DRE). RNS has been shown to be safe and effective in reducing seizure frequency in patients with DRE. Methods: We performed a retrospective cohort study of patients with DRE implanted with the RNS system at our institution between 2017 and 2024. The patients had at least 6 months of clinical follow-up and two RNS programming sessions postimplantation. We collected data on patient demographics and postimplantation seizure frequency. Efficacy was assessed as the median percent change in postimplantation seizure frequency compared to baseline, as well as responder rate defined as >50% reduction in seizures. A one-way analysis of variance test was used to assess differences in mean postoperative seizure frequency across all lead placement groups, and Fisher’s exact test was used to analyze differences in the proportion of patients achieving a postimplantation Engel classification of ≤2B. Results: Thirty patients were implanted with the RNS system at our institution between 2017 and 2024. Seventy-three percent of patients were male (n = 22), and the median age at RNS implantation was 36.5 years (interquartile range: 25–46). The mean seizure frequency reduction was 71.4 (±20.9), with a proportion of patients achieving a >50% seizure frequency reduction (responder rate) at 70% postimplantation, four patients had Engel 1A/1B outcome, 17 patients had Engel 2B outcome, and nine patients had achieved Engel 3A outcome. None of the patients had Engel 4 outcome at the last follow-up visit. Interestingly, the use of cenobamate had a statistically significant relationship with achieving a postoperative Engel 2B or better classification (P = 0.03) as well as prior vagal nerve stimulation placement (P < 0.001). Conclusion: RNS system is a safe and effective treatment for DRE. The responder rate in our cohort is consistent with the seizure outcomes reported in the literature. Additional studies need to characterize the differences between RNS responders and nonresponders.

29 February 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
TPTommy Pan
Tommy Pan
BGBrianne M Giuffrida
Brianne M Giuffrida
ATAmol H Trivedi
Amol H Trivedi
DCDom Contestabile
Dom Contestabile
PVPraveer Vyas
Praveer Vyas
SRSteven M. Regal
Steven M. Regal
Orthopedic costs associated with gunshot wounds (GSWs) totaled approximately USD 510 million from 2005 to 2014. Previous studies have identified differences in injuries associated with self-inflicted (SI) GSWs; however, there remains a gap in understanding injury patterns. This study aims to expand upon the current literature and shed light on injury patterns and outcomes associated with SI vs. non-self-inflicted (NSI) GSWs. This is a retrospective cohort study of upper extremity GSWs from January 2012 to December 2022. Data were analyzed using the two-sample t-test, Pearson’s chi-squared test, and Fisher’s exact test. SI GSWs tended to be high-velocity GSWs and occurred more often in distal locations compared to NSI GSWs (p = 0.0014 and p < 0.0001, respectively). SI GSWs were associated with higher Gustilo–Anderson (GA) and Tscherne classifications (p < 0.0001 and p = 0.0048, respectively) and with a greater frequency of neurovascular damage (p = 0.0048). There was no difference in fracture rate or need for operative intervention between the groups. GA and Tscherne classifications were associated with the need for and type of surgery (p < 0.0001), with a higher classification being associated with more intricate operative intervention; however, GSW velocity was not associated with operative need (p = 0.42). Our findings demonstrate that velocity, wound grading systems, and other factors are associated with the manner in which GSWs to the upper extremity are inflicted and may thus have potential for use in the prediction of injury patterns and planning of trauma management and surgical intervention.